Loading...

Ocuphire Pharma, Inc.

OCUP•NASDAQ
HealthcareBiotechnology
$1.17
$-0.16(-12.03%)

Ocuphire Pharma, Inc. (OCUP) Stock Overview

Explore Ocuphire Pharma, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for OCUPStats details for OCUP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for OCUPAnalyst Recommendations details for OCUP are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.

CEO

Mr. George Magrath M.B.A., M.D., M.S.

Employees

14

Headquarters

37000 Grand River Avenue, Farmington Hills, MI

Founded

2005

Frequently Asked Questions